Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income of -$111.31M in Q2 FY2026
Q2 FY2026 net income was -$111.31M.
What to watch
Whether net income reaches the consensus estimate of -$453M (+204.1%) for the fiscal year ending Dec 2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$111.31M+41.1% QoQ
- Last fiscal yearDec 2025
- -$148.96M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +204.1% | — |
| 3-year CAGR | — | +53.0% | — |
| 5-year CAGR | +17.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (148.96M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (148.96M) | — |
Net Income vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 net income of $148.96M is the 2nd largest of the 10 companies compared; the peer median is $91.08M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $534.8M | +211.7% | +73.5% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $148.96M | — | — | — |
| LTM Jun 2026 | $147.97M | -10.7% | +108.0% | 2078.0% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $145.1M | +80.3% | +49.3% | — |
| LTM Mar 2026 | $110M | +489.6% | — | — | |
| LTM Mar 2026 | $108M | +21.2% | +44.8% | — | |
| LTM Mar 2026 | $91.08M | +0.9% | +1.3% | 253002.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M | +26.6% | +26.6% | 871.8% |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $918K | +104.2% | +17.5% | 2.5% | |
| Peer median (excluding KLRA) | $91.08M | +26.6% | +35.7% | 1474.9% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (148.96M) |
| Depreciation & Amortization | 310K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 10.94M |
| Change in Working Capital | 16.78M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 4.69M |
| Other Working Capital | 12.09M |
| Other Non-Cash Items | 714K |
| Operating Cash Flow | (120.21M) |
| Capital Expenditures | (2.09M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (632.16M) |
| Sales of Investments | 141.65M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (492.6M) |
| Debt Repayment | 100M |
| Common Stock Issued | 498.97M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (499.19M) |
| Financing Cash Flow | 598.66M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | (14.15M) |
| Free Cash Flow | (122.3M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.